Strain Name:

B6;129S4-Pparatm1Gonz/J

Stock Number:

008154

Order this mouse

Availability:

Repository- Live

Use Restrictions Apply, see Terms of Use
Ppara deficient mutant mice exhibit increased gonadal adipose tissue stores, abnormal epidermal development and delayed wound healing. This mutant mouse strain may be useful in studies of lipid metabolism, cell proliferation, diabetes, obesity, and wound healing.

Description

Strain Information

Former Names B6.129S4-Pparatm1Gonz/J    (Changed: 02-FEB-10 )
Type Mutant Stock; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Mating SystemHomozygote x Homozygote         (Female x Male)   05-SEP-08
Specieslaboratory mouse
GenerationN10+F15 (11-DEC-13)
Generation Definitions
 
Donating InvestigatorDr. Frank Gonzalez,   National Institutes of Health

Description
Mice homozygous for the targeted mutation are viable and fertile. An altered response to a group of compounds (peroxisome proliferators) that induce peroxisome proliferation and hepatocarcinogenesis is observed. No peroxisome proliferation response is detected when these mice are challenged with classical peroxisome proliferators. Typically, such a response includes hepatomegaly, peroxisome proliferation and transcriptional activation of a set of target enzyme genes. Accumulation of lipid droplets observed in liver tissue suggests that Ppara is involved in maintaining the homeostasis of hepatic lipid metabolism. Homozygotes exhibit increased gonadal adipose tissue stores, abnormal epidermal development and delayed wound healing. This mutant mouse strain may be useful in studies of lipid metabolism, cell proliferation, diabetes, obesity, and wound healing.

Development
A targeting vector containing neomycin resistance and herpes simplex virus thymidine kinase genes was used to disrupt exon 8, which encodes the ligand binding domain. The construct was electroporated into 129S4/SvJae derived J1 embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6N blastocysts. The mice were initially maintained on a 129S4/SvJae background, and then were backcrossed for 10 generations on to the C57BL/6J background (please see note about SNP analysis below). Heterozygotes were then intercrossed to generate homozygotes. Upon arrival at The Jackson Laboratory, the mice were crossed to C57BL/6J (Stock No. 000664) at least once to establish the colony.

A 27 SNP (single nucleotide polymorphism) panel analysis performed by The Jackson Laboratory revealed 3 of 27 markers (on chromsomes 3, 12 and 15) that were not C57BL/6 allele-type. These markers are 129S4/SvJae allele-type and suggest the strain was not completely backcrossed prior to arrival at The Jackson Laboratory.

Control Information

  Control
   000664 C57BL/6J (approximate)
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Pparatm1Gonz allele
003580   129S4/SvJae-Pparatm1Gonz/J
View Strains carrying   Pparatm1Gonz     (1 strain)

Strains carrying other alleles of Ppara
012379   B6.Cg-Tg(Ckm-Ppara)HEDpk/J
012389   B6.Cg-Tg(Myh6-Ppara)404-3Dpk/J
012382   B6.Cg-Tg(Myh6-Ppara)404-4Dpk/J
View Strains carrying other alleles of Ppara     (3 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Peroxisome Proliferator-Activated Receptor-Alpha; PPARA   (PPARA)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Pparatm1Gonz/Pparatm1Gonz

        involves: 129S4/SvJae * C57BL/6N
  • mortality/aging
  • increased sensitivity to induced morbidity/mortality
    • inhibition of mitochondrial long chain fatty acid transport results the death of all male mutants but only 25% (2/8) of female mutants, no wild-types died as a result of this treatment   (MGI Ref ID J:50024)
    • intraperitoneal injection of 100ul of a 50% dextrose solution rescues these mice   (MGI Ref ID J:50024)
    • estradiol pretreatment rescues these male mice   (MGI Ref ID J:50024)
  • cardiovascular system phenotype
  • abnormal myocardial fiber morphology   (MGI Ref ID J:50024)
  • cardiomyopathy
    • the cardiomyopathic effects (increase in biventricular weight to body weight ratio, increase in left ventricular mass index, hypertrophy) of diabetes are not seen in insulin deficient mutants   (MGI Ref ID J:81834)
  • homeostasis/metabolism phenotype
  • decreased glycogen level
    • in male mutants compared to female mutants inhibition of mitochondrial long chain fatty acid transport produces a marked decrease in hepatic glycogen levels   (MGI Ref ID J:50024)
  • delayed wound healing
    • wound healing is delayed during the first 4 days post wounding   (MGI Ref ID J:71272)
    • recruitment of neutrophils and monocytes is impaired in mutants on day 1 post wounding   (MGI Ref ID J:71272)
  • hypoglycemia
    • male null mice develop severe hypoglycemia in response to CPT I inhibition   (MGI Ref ID J:50024)
    • estradiol rescues male null mice from the CPT I-induced death and impairment in lipid and glucose homeostasis   (MGI Ref ID J:50024)
  • liver/biliary system phenotype
  • abnormal hepatocyte morphology
    • the number of liver peroxisomes does not increase after treatment with peroxisome proliferators   (MGI Ref ID J:25516)
  • enlarged liver
    • homozygotes do not develop liver enlargement following treatment with peroxisome proliferators   (MGI Ref ID J:25516)
  • hepatic steatosis
    • lipid droplets accumulate in livers of mutant mice treated with peroxisome proliferators   (MGI Ref ID J:25516)
    • inhibition of mitochondrial long chain fatty acid transport resulted in fatty degeneration of the liver   (MGI Ref ID J:50024)
    • in male mutants almost all the accumulated lipid is triglyceride   (MGI Ref ID J:50024)
  • muscle phenotype
  • abnormal myocardial fiber morphology   (MGI Ref ID J:50024)
  • cardiomyopathy
    • the cardiomyopathic effects (increase in biventricular weight to body weight ratio, increase in left ventricular mass index, hypertrophy) of diabetes are not seen in insulin deficient mutants   (MGI Ref ID J:81834)
  • integument phenotype
  • abnormal epidermal layer morphology   (MGI Ref ID J:81021)
    • abnormal epidermis stratum corneum morphology
      • between E18.5 and birth mutants display a delay in cornified layer development with a significant reduction in the number of cell layers   (MGI Ref ID J:81021)
      • processing of lamellar bilayers at the level of the first extracellular space above the stratum granulosum- cornified layer interface is delayed at E18.5   (MGI Ref ID J:81021)
      • no defect in lamellar bilayers is seen in adults   (MGI Ref ID J:81021)

Pparatm1Gonz/Pparatm1Gonz

        involves: 129S4/SvJae * C57BL/6J
  • homeostasis/metabolism phenotype
  • abnormal glucose homeostasis
    • in a hyperinsulinemic-euglycemic clamp study, peripheral glucose disposal in mice fed a high fat diet is improved compared to in similarly treated wild-type mice   (MGI Ref ID J:129848)
    • improved glucose tolerance
      • when fed a high fat diet compared with similarly treated wild-type mice   (MGI Ref ID J:129848)
    • increased insulin sensitivity
      • when fed a high fat diet compared with similarly treated wild-type mice   (MGI Ref ID J:129848)
  • increased susceptibility to diet-induced obesity
    • when fed a high fat diet   (MGI Ref ID J:129848)
  • increased triglyceride level
    • in the gastrocnemius when fed a high fat diet   (MGI Ref ID J:129848)
  • muscle phenotype
  • abnormal muscle cell glucose uptake
    • when fed a high fat diet, muscle glucose uptake is improved compared with similarly treated wild-type mice   (MGI Ref ID J:129848)
  • growth/size/body phenotype
  • increased susceptibility to diet-induced obesity
    • when fed a high fat diet   (MGI Ref ID J:129848)
  • cellular phenotype
  • abnormal muscle cell glucose uptake
    • when fed a high fat diet, muscle glucose uptake is improved compared with similarly treated wild-type mice   (MGI Ref ID J:129848)

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Pparatm1Gonz/Pparatm1Gonz

        129S4/SvJae-Pparatm1Gonz
  • mortality/aging
  • increased sensitivity to induced morbidity/mortality
    • 2 males out of 32 (male and female) mutants did not survive a 48 hour fast   (MGI Ref ID J:56056)
  • adipose tissue phenotype
  • increased gonadal fat pad weight
    • gonadal adipose stores are significantly larger in both female and male mutants   (MGI Ref ID J:72185)
  • growth/size/body phenotype
  • increased body weight
    • body weight is significantly elevated in male mutants on a 129S4/SvJae background compared to wild-type   (MGI Ref ID J:72185)
  • homeostasis/metabolism phenotype
  • abnormal circulating HDL cholesterol level
    • serum concentrations of HDL cholesterol are significantly higher in 9 month-old mutants on a 129S4/SvJae background compared to wild-type   (MGI Ref ID J:72185)
  • abnormal circulating ketone body level
    • fasting did not increase plasma ketone levels despite development of hypoglycemia   (MGI Ref ID J:56056)
  • abnormal glucose homeostasis
    • in fasted mutants the initial drop in mean blood glucose levels is significantly greater than in fasted wild-types   (MGI Ref ID J:56056)
    • abnormal circulating glucose level
      • mutants do not respond to high fat diet with an increase in plasma glucose   (MGI Ref ID J:72932)
    • abnormal circulating insulin level
      • mutants do not respond to high fat diet with an increase in insulin levels   (MGI Ref ID J:72932)
    • insulin resistance
      • mutants on a 129S4/SvJae background fed a high fat diet do not develop insulin resistance   (MGI Ref ID J:72932)
  • increased circulating cholesterol level
    • serum concentrations of cholesterol are significantly higher in 9 month-old mutants on a 129S4/SvJae background compared to wild-type   (MGI Ref ID J:72185)
  • increased circulating free fatty acid level
    • after fasting mutants exhibit abnormally high levels of circulating free fatty acids   (MGI Ref ID J:56056)
  • liver/biliary system phenotype
  • enlarged liver
    • after a 48 hour fast livers in mutant mice are slightly enlarged and appear pale   (MGI Ref ID J:56056)
  • hepatic steatosis
    • in 6 month old mutants hepatic accumulation of lipids is increased   (MGI Ref ID J:72185)
    • lipid accumulation in the hepatocytes of fasted mutants is massive and homogeneous rather than exhibiting a regional pattern as in wild-types   (MGI Ref ID J:56056)
    • the majority of the lipid accumulation is in the triglyceride fraction   (MGI Ref ID J:56056)
  • cardiovascular system phenotype
  • abnormal myocardium layer morphology
    • patchy regions of neutral lipid accumulation are found in the myocardium after fasting   (MGI Ref ID J:56056)

Pparatm1Gonz/Pparatm1Gonz

        B6.129S4-Pparatm1Gonz
  • adipose tissue phenotype
  • increased gonadal fat pad weight
    • gonadal adipose stores are significantly larger in both female and male mutants   (MGI Ref ID J:72185)
  • homeostasis/metabolism phenotype
  • abnormal circulating glucose level
    • mutants do not respond to high fat diet with an increase in plasma glucose   (MGI Ref ID J:72932)
  • abnormal circulating insulin level
    • mutants do not respond to high fat diet with an increase in insulin levels   (MGI Ref ID J:72932)
  • increased circulating triglyceride level
    • serum concentrations of triglycerides are significantly higher in 9 month-old mutants on a C57BL/6N background   (MGI Ref ID J:72185)
  • liver/biliary system phenotype
  • hepatic steatosis
    • in 6 month old mutants hepatic accumulation of lipids is increased   (MGI Ref ID J:72185)

Pparatm1Gonz/Pparatm1Gonz

        involves: C57BL/6
  • integument phenotype
  • abnormal epidermal layer morphology   (MGI Ref ID J:64345)
    • abnormal keratinocyte differentiation
      • foci of keratinocytes with nuclei are found in the stratum corneum   (MGI Ref ID J:64345)
      • mutants do not respond to peroxisome proliferators with thinning of the epidermis   (MGI Ref ID J:64345)
    • decreased keratohyalin granule number
      • fewer keratohylin granules within the granular cells   (MGI Ref ID J:64345)
    • thin epidermis stratum granulosum
      • the granular layer is thinner   (MGI Ref ID J:64345)
  • cellular phenotype
  • abnormal keratinocyte differentiation
    • foci of keratinocytes with nuclei are found in the stratum corneum   (MGI Ref ID J:64345)
    • mutants do not respond to peroxisome proliferators with thinning of the epidermis   (MGI Ref ID J:64345)

Pparatm1Gonz/Pparatm1Gonz

        involves: 129S4/SvJae
  • cardiovascular system phenotype
  • abnormal cardiovascular system physiology
    • starvation stress and starvation plus high temperature stress significantly decrease the ATP concentration and increase the calcium concentration in hearts of mutants but not controls   (MGI Ref ID J:63801)
    • abnormal myocardial fiber physiology
      • the capacity for constitutive myocardial beta-oxidation of the medium and long chain fatty acids, octanoic acid and palmitic acid, is reduced compared to wild-type, indicating impaired mitochondrial fatty acid catabolism   (MGI Ref ID J:63801)
    • cardiomyopathy
      • exhibit age-dependent cardiac damage   (MGI Ref ID J:63801)
    • decreased systemic arterial systolic blood pressure
      • seen at 16 and 32 weeks of age   (MGI Ref ID J:63801)
    • heart inflammation
      • inflammatory infiltrates are predominantly composed of macrophages with few lymphocytes and neutrophils   (MGI Ref ID J:63801)
    • hypotension
      • seen in older mutants   (MGI Ref ID J:63801)
  • abnormal myocardial fiber morphology
    • cristae of mitochondria increase in number and density in myocardial cells at 16 and 32 weeks of age   (MGI Ref ID J:63801)
    • myocardial fiber degeneration
      • hearts at 16 weeks of age show myocardial degeneration associated with contraction band necrosis   (MGI Ref ID J:63801)
  • abnormal vascular endothelial cell morphology
    • number of caveolae in the cardiac capillary endothelium is increased   (MGI Ref ID J:63801)
  • cardiac fibrosis
    • hearts at 16 weeks of age show a little focal fibrosis and by 32 weeks of age, see diffuse fibrosis occupying 1/3 of the inner wall of the myocardium   (MGI Ref ID J:63801)
  • myocardial necrosis
    • exhibit contraction band necrosis   (MGI Ref ID J:63801)
  • immune system phenotype
  • heart inflammation
    • inflammatory infiltrates are predominantly composed of macrophages with few lymphocytes and neutrophils   (MGI Ref ID J:63801)
  • muscle phenotype
  • abnormal myocardial fiber morphology
    • cristae of mitochondria increase in number and density in myocardial cells at 16 and 32 weeks of age   (MGI Ref ID J:63801)
    • myocardial fiber degeneration
      • hearts at 16 weeks of age show myocardial degeneration associated with contraction band necrosis   (MGI Ref ID J:63801)
  • cardiomyopathy
    • exhibit age-dependent cardiac damage   (MGI Ref ID J:63801)
  • homeostasis/metabolism phenotype
  • abnormal fatty acid oxidation
  • decreased circulating glucose level
    • there is a 25% reduction in fasting glucose levels   (MGI Ref ID J:127793)
  • impaired adaptive thermogenesis   (MGI Ref ID J:176083)
  • increased circulating cholesterol level
    • over 60% increase in serum cholesterol levels   (MGI Ref ID J:127793)
  • increased circulating free fatty acid level
    • 50% increase in nonesterifed fatty acids in serum of mice fed a zero fat diet   (MGI Ref ID J:127793)
  • increased circulating insulin level
    • fasting insulin leves tended to be higher regardless of diet   (MGI Ref ID J:127793)
  • integument phenotype
  • *normal* integument phenotype
    • no epidermal phenotype is apparent; epidermal layer and surface lipid distribution appear normal   (MGI Ref ID J:109090)
  • cellular phenotype
  • abnormal fatty acid oxidation
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Cell Biology Research
Genes Regulating Growth and Proliferation

Diabetes and Obesity Research
Obesity Without Diabetes
      diet-induced

Internal/Organ Research
Wound Healing
      delayed/impaired

Metabolism Research
Lipid Metabolism

Pparatm1Gonz related

Diabetes and Obesity Research
Obesity Without Diabetes
      diet-induced

Internal/Organ Research
Wound Healing
      delayed/impaired

Metabolism Research

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Pparatm1Gonz
Allele Name targeted mutation 1, Frank J Gonzalez
Allele Type Targeted (Null/Knockout)
Common Name(s) PPAR-alpha-; PPARalpha-; PPARalpha-null; PparatniJGonz; mPPARalpha-;
Mutation Made By Christopher Coakley,   Laboratory of Metabolism, NCI
Strain of Origin129S4/SvJae
ES Cell Line NameJ1
ES Cell Line Strain129S4/SvJae
Gene Symbol and Name Ppara, peroxisome proliferator activated receptor alpha
Chromosome 15
Gene Common Name(s) 4933429D07Rik; AI118064; AW742785; NR1C1; PPAR; PPAR-alpha; PPARalpha; Ppar; RIKEN cDNA 4933429D07 gene; expressed sequence AI118064; expressed sequence AW742785; hPPAR; peroxisome proliferator activated receptor;
Molecular Note A neomycin resistance cassette replaced 83 bp of the coding sequence in exon 8. Northern blot analysis did not detect a transcript of wild-type size on RNA derived from liver of homozygous mice. An larger abnormal transcript was detected. Western blotanalysis did not detect PPARA protein in extracts derived from livers of homozygous mice. [MGI Ref ID J:25516] [MGI Ref ID J:91859]

Genotyping

Genotyping Information

Genotyping Protocols

Ppara tm1Gonz, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Lee SS; Pineau T; Drago J; Lee EJ; Owens JW; Kroetz DL; Fernandez-Salguero PM; Westphal H; Gonzalez FJ. 1995. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15(6):3012-22. [PubMed: 7539101]  [MGI Ref ID J:25516]

Additional References

Pparatm1Gonz related

Abbott BD; Wolf CJ; Schmid JE; Das KP; Zehr RD; Helfant L; Nakayama S; Lindstrom AB; Strynar MJ; Lau C. 2007. Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha. Toxicol Sci 98(2):571-81. [PubMed: 17488742]  [MGI Ref ID J:123378]

Abdelmegeed MA; Moon KH; Hardwick JP; Gonzalez FJ; Song BJ. 2009. Role of peroxisome proliferator-activated receptor-alpha in fasting-mediated oxidative stress. Free Radic Biol Med 47(6):767-78. [PubMed: 19539749]  [MGI Ref ID J:152568]

Abdelmegeed MA; Yoo SH; Henderson LE; Gonzalez FJ; Woodcroft KJ; Song BJ. 2011. PPAR{alpha} Expression Protects Male Mice from High Fat-Induced Nonalcoholic Fatty Liver. J Nutr 141(4):603-10. [PubMed: 21346097]  [MGI Ref ID J:170838]

Ahmadian M; Abbott MJ; Tang T; Hudak CS; Kim Y; Bruss M; Hellerstein MK; Lee HY; Samuel VT; Shulman GI; Wang Y; Duncan RE; Kang C; Sul HS. 2011. Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. Cell Metab 13(6):739-48. [PubMed: 21641555]  [MGI Ref ID J:176083]

Akiyama TE; Nicol CJ; Fievet C; Staels B; Ward JM; Auwerx J; Lee SS; Gonzalez FJ; Peters JM. 2001. Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J Biol Chem 276(42):39088-93. [PubMed: 11495927]  [MGI Ref ID J:72185]

Al Kholaifi A; Amer A; Jeffery B; Gray TJ; Roberts RA; Bell DR. 2008. Species-specific kinetics and zonation of hepatic DNA synthesis induced by ligands of PPARalpha. Toxicol Sci 104(1):74-85. [PubMed: 18375545]  [MGI Ref ID J:139596]

Albrecht PP; Torsell NE; Krishnan P; Ehresman DJ; Frame SR; Chang SC; Butenhoff JL; Kennedy GL; Gonzalez FJ; Peters JM. 2013. A Species Difference in the Peroxisome Proliferator-Activated Receptor alpha-Dependent Response to the Developmental Effects of Perfluorooctanoic Acid. Toxicol Sci 131(2):568-82. [PubMed: 23143925]  [MGI Ref ID J:192820]

Anderson SP; Howroyd P; Liu J; Qian X; Bahnemann R; Swanson C; Kwak MK; Kensler TW; Corton JC. 2004. The transcriptional response to a peroxisome proliferator-activated receptor alpha agonist includes increased expression of proteome maintenance genes. J Biol Chem 279(50):52390-8. [PubMed: 15375163]  [MGI Ref ID J:95180]

Anderson SP; Yoon L; Richard EB; Dunn CS; Cattley RC; Corton JC. 2002. Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice. Hepatology 36(3):544-54. [PubMed: 12198646]  [MGI Ref ID J:105933]

Aoyama T; Peters JM; Iritani N; Nakajima T; Furihata K; Hashimoto T; Gonzalez FJ. 1998. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha J Biol Chem 273(10):5678-84. [PubMed: 9488698]  [MGI Ref ID J:46203]

Atherton HJ; Bailey NJ; Zhang W; Taylor J; Major H; Shockcor J; Clarke K; Griffin JL. 2006. A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol Genomics 27(2):178-86. [PubMed: 16868074]  [MGI Ref ID J:113654]

Atherton HJ; Jones OA; Malik S; Miska EA; Griffin JL. 2008. A comparative metabolomic study of NHR-49 in Caenorhabditis elegans and PPAR-alpha in the mouse. FEBS Lett 582(12):1661-6. [PubMed: 18435929]  [MGI Ref ID J:136252]

Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF. 2007. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 116(12):1404-12. [PubMed: 17724261]  [MGI Ref ID J:139843]

Backhed F; Ding H; Wang T; Hooper LV; Koh GY; Nagy A; Semenkovich CF; Gordon JI. 2004. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101(44):15718-23. [PubMed: 15505215]  [MGI Ref ID J:93455]

Badman MK; Pissios P; Kennedy AR; Koukos G; Flier JS; Maratos-Flier E. 2007. Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARalpha and Is a Key Mediator of Hepatic Lipid Metabolism in Ketotic States. Cell Metab 5(6):426-437. [PubMed: 17550778]  [MGI Ref ID J:129854]

Bagattin A; Hugendubler L; Mueller E. 2010. Transcriptional coactivator PGC-1alpha promotes peroxisomal remodeling and biogenesis. Proc Natl Acad Sci U S A 107(47):20376-81. [PubMed: 21059926]  [MGI Ref ID J:166589]

Bandsma RH; Van Dijk TH; Harmsel At A; Kok T; Reijngoud DJ; Staels B; Kuipers F. 2004. Hepatic de novo synthesis of glucose 6-phosphate is not affected in peroxisome proliferator-activated receptor alpha-deficient mice but is preferentially directed toward hepatic glycogen stores after a short term fast. J Biol Chem 279(10):8930-7. [PubMed: 14688286]  [MGI Ref ID J:88489]

Bedu E; Desplanches D; Pequignot J; Bordier B; Desvergne B. 2007. Double gene deletion reveals the lack of cooperation between PPARalpha and PPARbeta in skeletal muscle. Biochem Biophys Res Commun 357(4):877-81. [PubMed: 17466944]  [MGI Ref ID J:121769]

Benameur T; Tual-Chalot S; Andriantsitohaina R; Martinez MC. 2010. PPARalpha is essential for microparticle-induced differentiation of mouse bone marrow-derived endothelial progenitor cells and angiogenesis. PLoS One 5(8):. [PubMed: 20811625]  [MGI Ref ID J:163995]

Berger JH; Charron MJ; Silver DL. 2012. Major facilitator superfamily domain-containing protein 2a (MFSD2A) has roles in body growth, motor function, and lipid metabolism. PLoS One 7(11):e50629. [PubMed: 23209793]  [MGI Ref ID J:194781]

Bernal-Mizrachi C; Weng S; Feng C; Finck BN; Knutsen RH; Leone TC; Coleman T; Mecham RP; Kelly DP; Semenkovich CF. 2003. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 9(8):1069-75. [PubMed: 12847522]  [MGI Ref ID J:84844]

Bernal-Mizrachi C; Xiaozhong L; Yin L; Knutsen RH; Howard MJ; Arends JJ; Desantis P; Coleman T; Semenkovich CF. 2007. An afferent vagal nerve pathway links hepatic PPARalpha activation to glucocorticoid-induced insulin resistance and hypertension. Cell Metab 5(2):91-102. [PubMed: 17276352]  [MGI Ref ID J:129769]

Bihan H; Rouault C; Reach G; Poitout V; Staels B; Guerre-Millo M. 2005. Pancreatic islet response to hyperglycemia is dependent on peroxisome proliferator-activated receptor alpha (PPARalpha). FEBS Lett 579(11):2284-8. [PubMed: 15848159]  [MGI Ref ID J:98237]

Bonzo JA; Brocker C; Jiang C; Wang RH; Deng CX; Gonzalez FJ. 2014. Hepatic sirtuin 1 is dispensable for fibrate-induced peroxisome proliferator-activated receptor-alpha function in vivo. Am J Physiol Endocrinol Metab 306(7):E824-37. [PubMed: 24496310]  [MGI Ref ID J:212297]

Bunger M; van den Bosch HM; van der Meijde J; Kersten S; Hooiveld GJ; Muller M. 2007. Genome-wide analysis of PPARalpha activation in murine small intestine. Physiol Genomics 30(2):192-204. [PubMed: 17426115]  [MGI Ref ID J:123868]

Calleja C; Messaddeq N; Chapellier B; Yang H; Krezel W; Li M; Metzger D; Mascrez B; Ohta K; Kagechika H; Endo Y; Mark M; Ghyselinck NB; Chambon P. 2006. Genetic and pharmacological evidence that a retinoic acid cannot be the RXR-activating ligand in mouse epidermis keratinocytes. Genes Dev 20(11):1525-38. [PubMed: 16751185]  [MGI Ref ID J:109090]

Campbell FM; Kozak R; Wagner A; Altarejos JY; Dyck JR; Belke DD; Severson DL; Kelly DP; Lopaschuk GD. 2002. A role for peroxisome proliferator-activated receptor alpha (PPARalpha ) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 277(6):4098-103. [PubMed: 11734553]  [MGI Ref ID J:74536]

Campolongo P; Roozendaal B; Trezza V; Cuomo V; Astarita G; Fu J; McGaugh JL; Piomelli D. 2009. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proc Natl Acad Sci U S A 106(19):8027-31. [PubMed: 19416833]  [MGI Ref ID J:148403]

Canaple L; Rambaud J; Dkhissi-Benyahya O; Rayet B; Tan NS; Michalik L; Delaunay F; Wahli W; Laudet V. 2006. Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock. Mol Endocrinol 20(8):1715-27. [PubMed: 16556735]  [MGI Ref ID J:110937]

Chakravarthy MV; Pan Z; Zhu Y; Tordjman K; Schneider JG; Coleman T; Turk J; Semenkovich CF. 2005. 'New' hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab 1(5):309-22. [PubMed: 16054078]  [MGI Ref ID J:127793]

Chau BN; Xin C; Hartner J; Ren S; Castano AP; Linn G; Li J; Tran PT; Kaimal V; Huang X; Chang AN; Li S; Kalra A; Grafals M; Portilla D; MacKenna DA; Orkin SH; Duffield JS. 2012. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 4(121):121ra18. [PubMed: 22344686]  [MGI Ref ID J:183786]

Chen C; Hennig GE; Whiteley HE; Corton JC; Manautou JE. 2000. Peroxisome proliferator-activated receptor alpha-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure. Toxicol Sci 57(2):338-44. [PubMed: 11006363]  [MGI Ref ID J:126618]

Chen Y; Hu Y; Lin M; Jenkins AJ; Keech AC; Mott R; Lyons TJ; Ma JX. 2013. Therapeutic effects of PPARalpha agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 62(1):261-72. [PubMed: 23043158]  [MGI Ref ID J:208469]

Cheng X; Klaassen CD. 2008. Perfluorocarboxylic acids induce cytochrome P450 enzymes in mouse liver through activation of PPAR-alpha and CAR transcription factors. Toxicol Sci 106(1):29-36. [PubMed: 18648086]  [MGI Ref ID J:141993]

Cheung C; Akiyama TE; Ward JM; Nicol CJ; Feigenbaum L; Vinson C; Gonzalez FJ. 2004. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res 64(11):3849-54. [PubMed: 15172993]  [MGI Ref ID J:90303]

Costet P; Legendre C; More J; Edgar A; Galtier P; Pineau T. 1998. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 273(45):29577-85. [PubMed: 9792666]  [MGI Ref ID J:50914]

Cotter DG; Ercal B; d'Avignon DA; Dietzen DJ; Crawford PA. 2014. Impairments of hepatic gluconeogenesis and ketogenesis in PPARalpha-deficient neonatal mice. Am J Physiol Endocrinol Metab 307(2):E176-85. [PubMed: 24865983]  [MGI Ref ID J:215231]

Cuzzocrea S; Di Paola R; Mazzon E; Genovese T; Muia C; Centorrino T; Caputi AP. 2004. Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. Lab Invest 84(12):1643-54. [PubMed: 15492755]  [MGI Ref ID J:94816]

Cuzzocrea S; Mazzon E; Di Paola R; Peli A; Bonato A; Britti D; Genovese T; Muia C; Crisafulli C; Caputi AP. 2006. The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol 79(5):999-1010. [PubMed: 16501055]  [MGI Ref ID J:108666]

D'Argenio G; Petillo O; Margarucci S; Torpedine A; Calarco A; Koverech A; Boccia A; Paolella G; Peluso G. 2010. Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis. J Biol Chem 285(35):27078-87. [PubMed: 20558736]  [MGI Ref ID J:166186]

Dalen KT; Dahl T; Holter E; Arntsen B; Londos C; Sztalryd C; Nebb HI. 2007. LSDP5 is a PAT protein specifically expressed in fatty acid oxidizing tissues. Biochim Biophys Acta 1771(2):210-27. [PubMed: 17234449]  [MGI Ref ID J:120943]

Dalen KT; Ulven SM; Arntsen BM; Solaas K; Nebb HI. 2006. PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver. J Lipid Res 47(5):931-43. [PubMed: 16489205]  [MGI Ref ID J:109003]

Dallongeville J; Bauge E; Tailleux A; Peters JM; Gonzalez FJ; Fruchart JC; Staels B. 2001. Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil. J Biol Chem 276(7):4634-9. [PubMed: 11050100]  [MGI Ref ID J:124428]

De Souza AT; Dai X; Spencer AG; Reppen T; Menzie A; Roesch PL; He Y; Caguyong MJ; Bloomer S; Herweijer H; Wolff JA; Hagstrom JE; Lewis DL; Linsley PS; Ulrich RG. 2006. Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice. Nucleic Acids Res 34(16):4486-94. [PubMed: 16945951]  [MGI Ref ID J:117586]

Di Paola R; Impellizzeri D; Torre A; Mazzon E; Cappellani A; Faggio C; Esposito E; Trischitta F; Cuzzocrea S. 2012. Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia-reperfusion in mice. J Leukoc Biol 91(6):911-20. [PubMed: 22469754]  [MGI Ref ID J:184907]

Djouadi F; Brandt JM; Weinheimer CJ; Leone TC; Gonzalez FJ; Kelly DP. 1999. The role of the peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac lipid metabolism Prostaglandins Leukot Essent Fatty Acids 60(5-6):339-43. [PubMed: 10471118]  [MGI Ref ID J:59504]

Djouadi F; Weinheimer CJ; Saffitz JE; Pitchford C; Bastin J; Gonzalez FJ; Kelly DP. 1998. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice. J Clin Invest 102(6):1083-91. [PubMed: 9739042]  [MGI Ref ID J:50024]

Doi R; Oishi K; Ishida N. 2010. CLOCK regulates circadian rhythms of hepatic glycogen synthesis through transcriptional activation of Gys2. J Biol Chem 285(29):22114-21. [PubMed: 20430893]  [MGI Ref ID J:165365]

Duncan JG; Fong JL; Medeiros DM; Finck BN; Kelly DP. 2007. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 115(7):909-17. [PubMed: 17261654]  [MGI Ref ID J:130544]

Dunn SE; Ousman SS; Sobel RA; Zuniga L; Baranzini SE; Youssef S; Crowell A; Loh J; Oksenberg J; Steinman L. 2007. Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J Exp Med 204(2):321-30. [PubMed: 17261635]  [MGI Ref ID J:125374]

Durgan DJ; Smith JK; Hotze MA; Egbejimi O; Cuthbert KD; Zaha VG; Dyck JR; Abel ED; Young ME. 2006. Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin. Am J Physiol Heart Circ Physiol 290(6):H2480-97. [PubMed: 16428347]  [MGI Ref ID J:111844]

Erol E; Kumar LS; Cline GW; Shulman GI; Kelly DP; Binas B. 2004. Liver fatty acid binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPARalpha in fasting mice. FASEB J 18(2):347-9. [PubMed: 14656998]  [MGI Ref ID J:119163]

Faiola B; Falls JG; Peterson RA; Bordelon NR; Brodie TA; Cummings CA; Romach EH; Miller RT. 2008. PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742. Toxicol Sci 105(2):384-94. [PubMed: 18593727]  [MGI Ref ID J:139727]

Feingold KR; Grunfeld C; Heuer JG; Gupta A; Cramer M; Zhang T; Shigenaga JK; Patzek SM; Chan ZW; Moser A; Bina H; Kharitonenkov A. 2012. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology 153(6):2689-700. [PubMed: 22474187]  [MGI Ref ID J:186727]

Feingold KR; Wang Y; Moser A; Shigenaga JK; Grunfeld C. 2008. LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney. J Lipid Res 49(10):2179-87. [PubMed: 18574256]  [MGI Ref ID J:140368]

Fernandez-Espejo E; Ramiro-Fuentes S; Rodriguez de Fonseca F. 2009. The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine. Neuroscience 164(2):667-75. [PubMed: 19698765]  [MGI Ref ID J:155141]

Finck BN; Bernal-Mizrachi C; Han DH; Coleman T; Sambandam N; LaRiviere LL; Holloszy JO; Semenkovich CF; Kelly DP. 2005. A potential link between muscle peroxisome proliferator- activated receptor-alpha signaling and obesity-related diabetes. Cell Metab 1(2):133-44. [PubMed: 16054054]  [MGI Ref ID J:129848]

Finck BN; Gropler MC; Chen Z; Leone TC; Croce MA; Harris TE; Lawrence JC Jr; Kelly DP. 2006. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab 4(3):199-210. [PubMed: 16950137]  [MGI Ref ID J:129744]

Finck BN; Han X; Courtois M; Aimond F; Nerbonne JM; Kovacs A; Gross RW; Kelly DP. 2003. A critical role for PPARalpha -mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: Modulation by dietary fat content. Proc Natl Acad Sci U S A 100(3):1226-31. [PubMed: 12552126]  [MGI Ref ID J:81834]

Foreman JE; Chang SC; Ehresman DJ; Butenhoff JL; Anderson CR; Palkar PS; Kang BH; Gonzalez FJ; Peters JM. 2009. Differential hepatic effects of perfluorobutyrate mediated by mouse and human PPAR-alpha. Toxicol Sci 110(1):204-11. [PubMed: 19359353]  [MGI Ref ID J:149907]

Freigang S; Ampenberger F; Weiss A; Kanneganti TD; Iwakura Y; Hersberger M; Kopf M. 2013. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1alpha and sterile vascular inflammation in atherosclerosis. Nat Immunol 14(10):1045-53. [PubMed: 23995233]  [MGI Ref ID J:208219]

Fu J; Gaetani S; Oveisi F; Lo Verme J; Serrano A; Rodriguez De Fonseca F; Rosengarth A; Luecke H; Di Giacomo B; Tarzia G; Piomelli D. 2003. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425(6953):90-3. [PubMed: 12955147]  [MGI Ref ID J:85352]

Fujita K; Maeda N; Sonoda M; Ohashi K; Hibuse T; Nishizawa H; Nishida M; Hiuge A; Kurata A; Kihara S; Shimomura I; Funahashi T. 2008. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler Thromb Vasc Biol 28(5):863-70. [PubMed: 18309113]  [MGI Ref ID J:179566]

Gachon F; Leuenberger N; Claudel T; Gos P; Jouffe C; Fleury Olela F; de Mollerat du Jeu X; Wahli W; Schibler U. 2011. Proline- and acidic amino acid-rich basic leucine zipper proteins modulate peroxisome proliferator-activated receptor {alpha} (PPAR{alpha}) activity. Proc Natl Acad Sci U S A 108(12):4794-9. [PubMed: 21383142]  [MGI Ref ID J:170098]

Gan Z; Rumsey J; Hazen BC; Lai L; Leone TC; Vega RB; Xie H; Conley KE; Auwerx J; Smith SR; Olson EN; Kralli A; Kelly DP. 2013. Nuclear receptor/microRNA circuitry links muscle fiber type to energy metabolism. J Clin Invest 123(6):2564-75. [PubMed: 23676496]  [MGI Ref ID J:201439]

Garrido-Urbani S; Jemelin S; Deffert C; Carnesecchi S; Basset O; Szyndralewiez C; Heitz F; Page P; Montet X; Michalik L; Arbiser J; Ruegg C; Krause KH; Imhof B. 2011. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS One 6(2):e14665. [PubMed: 21326871]  [MGI Ref ID J:170891]

Gelinas R; Labarthe F; Bouchard B; Mc Duff J; Charron G; Young ME; Des Rosiers C. 2008. Alterations in carbohydrate metabolism and its regulation in PPARalpha null mouse hearts. Am J Physiol Heart Circ Physiol 294(4):H1571-80. [PubMed: 18223187]  [MGI Ref ID J:135352]

Genolet R; Kersten S; Braissant O; Mandard S; Tan NS; Bucher P; Desvergne B; Michalik L; Wahli W. 2005. Promoter rearrangements cause species-specific hepatic regulation of the glyoxylate reductase/hydroxypyruvate reductase gene by the peroxisome proliferator-activated receptor alpha. J Biol Chem 280(25):24143-52. [PubMed: 15840574]  [MGI Ref ID J:100843]

Genovese T; Mazzon E; Di Paola R; Muia C; Crisafulli C; Malleo G; Esposito E; Cuzzocrea S. 2006. Role of peroxisome proliferator-activated receptor-alpha in acute pancreatitis induced by cerulein. Immunology 118(4):559-70. [PubMed: 16764691]  [MGI Ref ID J:114493]

Georgiadi A; Lichtenstein L; Degenhardt T; Boekschoten MV; van Bilsen M; Desvergne B; Muller M; Kersten S. 2010. Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress. Circ Res 106(11):1712-21. [PubMed: 20378851]  [MGI Ref ID J:172706]

Gibbons GF; Patel D; Wiggins D; Knight BL. 2002. The functional efficiency of lipogenic and cholesterogenic gene expression in normal mice and in mice lacking the peroxisomal proliferator-activated receptor-alpha (PPAR-alpha). Adv Enzyme Regul 42:227-47. [PubMed: 12123718]  [MGI Ref ID J:79464]

Gizard F; Amant C; Barbier O; Bellosta S; Robillard R; Percevault F; Sevestre H; Krimpenfort P; Corsini A; Rochette J; Glineur C; Fruchart JC; Torpier G; Staels B. 2005. PPARalpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16. J Clin Invest 115(11):3228-3238. [PubMed: 16239970]  [MGI Ref ID J:102505]

Gloerich J; van Vlies N; Jansen GA; Denis S; Ruiter JP; van Werkhoven MA; Duran M; Vaz FM; Wanders RJ; Ferdinandusse S. 2005. A phytol-enriched diet induces changes in fatty acid metabolism in mice both via PPARalpha-dependent and -independent pathways. J Lipid Res 46(4):716-26. [PubMed: 15654129]  [MGI Ref ID J:98577]

Gloerich J; van den Brink DM; Ruiter JP; van Vlies N; Vaz FM; Wanders RJ; Ferdinandusse S. 2007. Metabolism of phytol to phytanic acid in the mouse, and the role of PPARalpha in its regulation. J Lipid Res 48(1):77-85. [PubMed: 17015885]  [MGI Ref ID J:117641]

Goh BC; Wu X; Evans AE; Johnson ML; Hill MR; Gimble JM. 2007. Food entrainment of circadian gene expression altered in PPARalpha(-/-) brown fat and heart. Biochem Biophys Res Commun 360(4):828-33. [PubMed: 17624301]  [MGI Ref ID J:123508]

Gonzalez-Aparicio R; Flores JA; Tasset I; Tunez I; Fernandez-Espejo E. 2011. Mice lacking the peroxisome proliferator-activated receptor alpha gene present reduced number of dopamine neurons in the substantia nigra without altering motor behavior or dopamine neuron decline over life. Neuroscience 186:161-9. [PubMed: 21463665]  [MGI Ref ID J:173954]

Grav HJ; Tronstad KJ; Gudbrandsen OA; Berge K; Fladmark KE; Martinsen TC; Waldum H; Wergedahl H; Berge RK. 2003. Changed energy state and increased mitochondrial beta-oxidation rate in liver of rats associated with lowered proton electrochemical potential and stimulated uncoupling protein 2 (UCP-2) expression: evidence for peroxisome proliferator-activated receptor-alpha independent induction of UCP-2 expression. J Biol Chem 278(33):30525-33. [PubMed: 12756242]  [MGI Ref ID J:120448]

Gremlich S; Nolan C; Roduit R; Burcelin R; Peyot ML; Delghingaro-Augusto V; Desvergne B; Michalik L; Prentki M; Wahli W. 2005. Pancreatic islet adaptation to fasting is dependent on peroxisome proliferator-activated receptor alpha transcriptional up-regulation of fatty acid oxidation. Endocrinology 146(1):375-82. [PubMed: 15459119]  [MGI Ref ID J:105462]

Guellich A; Damy T; Conti M; Claes V; Samuel JL; Pineau T; Lecarpentier Y; Coirault C. 2013. Tempol prevents cardiac oxidative damage and left ventricular dysfunction in the PPAR-alpha KO mouse. Am J Physiol Heart Circ Physiol 304(11):H1505-12. [PubMed: 23542920]  [MGI Ref ID J:198208]

Guellich A; Damy T; Lecarpentier Y; Conti M; Claes V; Samuel JL; Quillard J; Hebert JL; Pineau T; Coirault C. 2007. Role of oxidative stress in cardiac dysfunction of PPARalpha-/- mice. Am J Physiol Heart Circ Physiol 293(1):H93-H102. [PubMed: 17369471]  [MGI Ref ID J:126036]

Guerre-Millo M; Rouault C; Poulain P; Andre J; Poitout V; Peters JM; Gonzalez FJ; Fruchart JC; Reach G; Staels B. 2001. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 50(12):2809-14. [PubMed: 11723064]  [MGI Ref ID J:72932]

Guidotti LG; Eggers CM; Raney AK; Chi SY; Peters JM; Gonzalez FJ; McLachlan A. 1999. In vivo regulation of hepatitis B virus replication by peroxisome proliferators. J Virol 73(12):10377-86. [PubMed: 10559356]  [MGI Ref ID J:119843]

Guo D; Sarkar J; Suino-Powell K; Xu Y; Matsumoto K; Jia Y; Yu S; Khare S; Haldar K; Rao MS; Foreman JE; Monga SP; Peters JM; Xu HE; Reddy JK. 2007. Induction of Nuclear Translocation of Constitutive Androstane Receptor by Peroxisome Proliferator-activated Receptor {alpha} Synthetic Ligands in Mouse Liver. J Biol Chem 282(50):36766-76. [PubMed: 17962186]  [MGI Ref ID J:128919]

Gutgesell A; Wen G; Konig B; Koch A; Spielmann J; Stangl GI; Eder K; Ringseis R. 2009. Mouse carnitine-acylcarnitine translocase (CACT) is transcriptionally regulated by PPARalpha and PPARdelta in liver cells. Biochim Biophys Acta 1790(10):1206-16. [PubMed: 19577614]  [MGI Ref ID J:153436]

Hafstad AD; Khalid AM; Hagve M; Lund T; Larsen TS; Severson DL; Clarke K; Berge RK; Aasum E. 2009. Cardiac peroxisome proliferator-activated receptor-alpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischaemic functional loss. Cardiovasc Res 83(3):519-26. [PubMed: 19398469]  [MGI Ref ID J:167968]

Hashimoto T; Cook WS; Qi C; Yeldandi AV; Reddy JK; Rao MS. 2000. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 275(37):28918-28. [PubMed: 10844002]  [MGI Ref ID J:93972]

Hashimoto T; Fujita T; Usuda N; Cook W; Qi C; Peters JM; Gonzalez FJ; Yeldandi AV; Rao MS; Reddy JK. 1999. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem 274(27):19228-36. [PubMed: 10383430]  [MGI Ref ID J:56079]

Hasmall S; Orphanides G; James N; Pennie W; Hedley K; Soames A; Kimber I; Roberts R. 2002. Downregulation of lactoferrin by PPARalpha ligands: role in perturbation of hepatocyte proliferation and apoptosis. Toxicol Sci 68(2):304-13. [PubMed: 12151626]  [MGI Ref ID J:126177]

Hasmall SC; James NH; Macdonald N; Gonzalez FJ; Peters JM; Roberts RA. 2000. Suppression of mouse hepatocyte apoptosis by peroxisome proliferators: role of PPARalpha and TNFalpha. Mutat Res 448(2):193-200. [PubMed: 10725472]  [MGI Ref ID J:61128]

Hays T; Rusyn I; Burns AM; Kennett MJ; Ward JM; Gonzalez FJ; Peters JM. 2005. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26(1):219-27. [PubMed: 15447978]  [MGI Ref ID J:95013]

Hebbachi AM; Knight BL; Wiggins D; Patel DD; Gibbons GF. 2008. Peroxisome proliferator-activated receptor alpha deficiency abolishes the response of lipogenic gene expression to re-feeding: restoration of the normal response by activation of liver X receptor alpha. J Biol Chem 283(8):4866-76. [PubMed: 18079124]  [MGI Ref ID J:132145]

Hill MR; Clarke S; Rodgers K; Thornhill B; Peters JM; Gonzalez FJ; Gimble JM. 1999. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect Immun 67(7):3488-93. [PubMed: 10377130]  [MGI Ref ID J:55888]

Hondares E; Rosell M; Diaz-Delfin J; Olmos Y; Monsalve M; Iglesias R; Villarroya F; Giralt M. 2011. Peroxisome Proliferator-activated Receptor alpha (PPARalpha) Induces PPARgamma Coactivator 1alpha (PGC-1alpha) Gene Expression and Contributes to Thermogenic Activation of Brown Fat: INVOLVEMENT OF PRDM16. J Biol Chem 286(50):43112-22. [PubMed: 22033933]  [MGI Ref ID J:178692]

Hondares E; Rosell M; Gonzalez FJ; Giralt M; Iglesias R; Villarroya F. 2010. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab 11(3):206-12. [PubMed: 20197053]  [MGI Ref ID J:158741]

Howroyd P; Swanson C; Dunn C; Cattley RC; Corton JC. 2004. Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha). Toxicol Pathol 32(5):591-9. [PubMed: 15603543]  [MGI Ref ID J:93792]

Hu T; Foxworthy P; Siesky A; Ficorilli JV; Gao H; Li S; Christe M; Ryan T; Cao G; Eacho P; Michael MD; Michael LF. 2005. Hepatic peroxisomal fatty acid beta-oxidation is regulated by liver X receptor alpha. Endocrinology 146(12):5380-7. [PubMed: 16123164]  [MGI Ref ID J:129833]

Hu Y; Chen Y; Ding L; He X; Takahashi Y; Gao Y; Shen W; Cheng R; Chen Q; Qi X; Boulton ME; Ma JX. 2013. Pathogenic role of diabetes-induced PPAR-alpha down-regulation in microvascular dysfunction. Proc Natl Acad Sci U S A 110(38):15401-6. [PubMed: 24003152]  [MGI Ref ID J:201158]

Hunt MC; Yang YZ; Eggertsen G; Carneheim CM; Gafvels M; Einarsson C; Alexson SE. 2000. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. J Biol Chem 275(37):28947-53. [PubMed: 10867000]  [MGI Ref ID J:64578]

Huss JM; Torra IP; Staels B; Giguere V; Kelly DP. 2004. Estrogen-Related Receptor {alpha} Directs Peroxisome Proliferator-Activated Receptor {alpha} Signaling in the Transcriptional Control of Energy Metabolism in Cardiac and Skeletal Muscle. Mol Cell Biol 24(20):9079-9091. [PubMed: 15456881]  [MGI Ref ID J:93319]

IJpenberg A; Tan NS; Gelman L; Kersten S; Seydoux J; Xu J; Metzger D; Canaple L; Chambon P; Wahli W; Desvergne B. 2004. In vivo activation of PPAR target genes by RXR homodimers. EMBO J 23(10):2083-91. [PubMed: 15103326]  [MGI Ref ID J:115486]

Ijssennagger N; de Wit N; Muller M; van der Meer R. 2012. Dietary heme-mediated PPARalpha activation does not affect the heme-induced epithelial hyperproliferation and hyperplasia in mouse colon. PLoS One 7(8):e43260. [PubMed: 22905243]  [MGI Ref ID J:189901]

Inagaki T; Dutchak P; Zhao G; Ding X; Gautron L; Parameswara V; Li Y; Goetz R; Mohammadi M; Esser V; Elmquist JK; Gerard RD; Burgess SC; Hammer RE; Mangelsdorf DJ; Kliewer SA. 2007. Endocrine Regulation of the Fasting Response by PPARalpha-Mediated Induction of Fibroblast Growth Factor 21. Cell Metab 5(6):415-25. [PubMed: 17550777]  [MGI Ref ID J:129855]

Ip E; Farrell GC; Robertson G; Hall P; Kirsch R; Leclercq I. 2003. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38(1):123-32. [PubMed: 12829994]  [MGI Ref ID J:105844]

Islam KK; Knight BL; Frayn KN; Patel DD; Gibbons GF. 2005. Deficiency of PPARalpha disturbs the response of lipogenic flux and of lipogenic and cholesterogenic gene expression to dietary cholesterol in mouse white adipose tissue. Biochim Biophys Acta 1734(3):259-68. [PubMed: 15878692]  [MGI Ref ID J:100125]

Jones DC; Ding X; Zhang TY; Daynes RA. 2003. Peroxisome proliferator-activated receptor alpha negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation. J Immunol 171(1):196-203. [PubMed: 12816998]  [MGI Ref ID J:84058]

Kaipainen A; Kieran MW; Huang S; Butterfield C; Bielenberg D; Mostoslavsky G; Mulligan R; Folkman J; Panigrahy D. 2007. PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS ONE 2(2):e260. [PubMed: 17327920]  [MGI Ref ID J:129339]

Kamijo Y; Hora K; Kono K; Takahashi K; Higuchi M; Ehara T; Kiyosawa K; Shigematsu H; Gonzalez FJ; Aoyama T. 2007. PPARalpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol 18(12):3089-100. [PubMed: 17978304]  [MGI Ref ID J:148143]

Kamijo Y; Hora K; Nakajima T; Kono K; Takahashi K; Ito Y; Higuchi M; Kiyosawa K; Shigematsu H; Gonzalez FJ; Aoyama T. 2007. Peroxisome proliferator-activated receptor alpha protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate. J Am Soc Nephrol 18(1):176-88. [PubMed: 17135395]  [MGI Ref ID J:136008]

Kamijo Y; Hora K; Tanaka N; Usuda N; Kiyosawa K; Nakajima T; Gonzalez FJ; Aoyama T. 2002. Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules. J Am Soc Nephrol 13(7):1691-702. [PubMed: 12089364]  [MGI Ref ID J:103223]

Kang HW; Kanno K; Scapa EF; Cohen DE. 2010. Regulatory role for phosphatidylcholine transfer protein/StarD2 in the metabolic response to peroxisome proliferator activated receptor alpha (PPARalpha). Biochim Biophys Acta 1801(4):496-502. [PubMed: 20045742]  [MGI Ref ID J:164815]

Kersten S; Mandard S; Escher P; Gonzalez FJ; Tafuri S; Desvergne B; Wahli W. 2001. The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism. FASEB J 15(11):1971-8. [PubMed: 11532977]  [MGI Ref ID J:120162]

Kersten S; Mandard S; Tan NS; Escher P; Metzger D; Chambon P; Gonzalez FJ; Desvergne B; Wahli W. 2000. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene J Biol Chem 275(37):28488-93. [PubMed: 10862772]  [MGI Ref ID J:64473]

Kersten S; Seydoux J; Peters JM; Gonzalez FJ; Desvergne B; Wahli W. 1999. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103(11):1489-98. [PubMed: 10359558]  [MGI Ref ID J:119258]

Kim BH; Won YS; Kim EY; Yoon M; Nam KT; Oh GT; Kim DY. 2003. Phenotype of peroxisome proliferator-activated receptor-alpha(PPARalpha)deficient mice on mixed background fed high fat diet. J Vet Sci 4(3):239-44. [PubMed: 14685029]  [MGI Ref ID J:118734]

Kim H; Mendez R; Zheng Z; Chang L; Cai J; Zhang R; Zhang K. 2014. Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor alpha to regulate metabolic hormone FGF21. Endocrinology 155(3):769-82. [PubMed: 24424044]  [MGI Ref ID J:208810]

Knauf C; Rieusset J; Foretz M; Cani PD; Uldry M; Hosokawa M; Martinez E; Bringart M; Waget A; Kersten S; Desvergne B; Gremlich S; Wahli W; Seydoux J; Delzenne NM; Thorens B; Burcelin R. 2006. Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: Role in liver and brain. Endocrinology 147(9):4067-78. [PubMed: 16777972]  [MGI Ref ID J:129641]

Knight BL; Patel DD; Humphreys SM; Wiggins D; Gibbons GF. 2003. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. J Lipid Res 44(11):2049-58. [PubMed: 12897186]  [MGI Ref ID J:86775]

Kok T; Wolters H; Bloks VW; Havinga R; Jansen PL; Staels B; Kuipers F. 2003. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology 124(1):160-71. [PubMed: 12512040]  [MGI Ref ID J:81018]

Komatsu M; Tong Y; Li Y; Nakajima T; Li G; Hu R; Sugiyama E; Kamijo Y; Tanaka N; Hara A; Aoyama T. 2010. Multiple roles of PPARalpha in brown adipose tissue under constitutive and cold conditions. Genes Cells 15(2):91-100. [PubMed: 20002497]  [MGI Ref ID J:158538]

Komuves LG; Hanley K; Lefebvre AM; Man MQ; Ng DC; Bikle DD; Williams ML; Elias PM; Auwerx J; Feingold KR. 2000. Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol 115(3):353-60. [PubMed: 10951268]  [MGI Ref ID J:64345]

Konig B; Koch A; Giggel K; Dordschbal B; Eder K; Stangl GI. 2008. Monocarboxylate transporter (MCT)-1 is up-regulated by PPARalpha. Biochim Biophys Acta 1780(6):899-904. [PubMed: 18375207]  [MGI Ref ID J:136777]

Kono K; Kamijo Y; Hora K; Takahashi K; Higuchi M; Kiyosawa K; Shigematsu H; Gonzalez FJ; Aoyama T. 2009. PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells. Am J Physiol Renal Physiol 296(2):F328-36. [PubMed: 19036849]  [MGI Ref ID J:144724]

Konstandi M; Shah YM; Matsubara T; Gonzalez FJ. 2013. Role of PPARalpha and HNF4alpha in stress-mediated alterations in lipid homeostasis. PLoS One 8(8):e70675. [PubMed: 23967086]  [MGI Ref ID J:206357]

Kroetz DL; Yook P; Costet P; Bianchi P; Pineau T. 1998. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem 273(47):31581-9. [PubMed: 9813074]  [MGI Ref ID J:111695]

Kulozik P; Jones A; Mattijssen F; Rose AJ; Reimann A; Strzoda D; Kleinsorg S; Raupp C; Kleinschmidt J; Muller-Decker K; Wahli W; Sticht C; Gretz N; von Loeffelholz C; Stockmann M; Pfeiffer A; Stohr S; Dallinga-Thie GM; Nawroth PP; Diaz MB; Herzig S. 2011. Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemia. Cell Metab 13(4):389-400. [PubMed: 21459324]  [MGI Ref ID J:172247]

Lalloyer F; Vandewalle B; Percevault F; Torpier G; Kerr-Conte J; Oosterveer M; Paumelle R; Fruchart JC; Kuipers F; Pattou F; Fievet C; Staels B. 2006. Peroxisome Proliferator-Activated Receptor {alpha} Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets. Diabetes 55(6):1605-13. [PubMed: 16731822]  [MGI Ref ID J:111882]

Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Bauge E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A. 2011. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol 31(7):1573-9. [PubMed: 21474829]  [MGI Ref ID J:191472]

Lambert G; Jarnoux AL; Pineau T; Pape O; Chetiveaux M; Laboisse C; Krempf M; Costet P. 2006. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 147(10):4985-95. [PubMed: 16794006]  [MGI Ref ID J:129548]

Lan D; Silver DL. 2005. Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1. J Biol Chem 280(24):23390-6. [PubMed: 15837786]  [MGI Ref ID J:100280]

Le May C; Pineau T; Bigot K; Kohl C; Girard J; Pegorier JP. 2000. Reduced hepatic fatty acid oxidation in fasting PPARalpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression. FEBS Lett 475(3):163-6. [PubMed: 10869548]  [MGI Ref ID J:63062]

Lecarpentier Y; Krokidis X; Martin P; Pineau T; Hebert JL; Quillard J; Cortes-Morichetti M; Coirault C. 2008. Increased entropy production in diaphragm muscle of PPAR alpha knockout mice. J Theor Biol 250(1):92-102. [PubMed: 17980390]  [MGI Ref ID J:141458]

Lee SS; Chan WY; Lo CK; Wan DC; Tsang DS; Cheung WT. 2004. Requirement of PPARalpha in maintaining phospholipid and triacylglycerol homeostasis during energy deprivation. J Lipid Res 45(11):2025-37. [PubMed: 15342691]  [MGI Ref ID J:94139]

Lee WJ; Kim M; Park HS; Kim HS; Jeon MJ; Oh KS; Koh EH; Won JC; Kim MS; Oh GT; Yoon M; Lee KU; Park JY. 2006. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem Biophys Res Commun 340(1):291-5. [PubMed: 16364253]  [MGI Ref ID J:104210]

Lee Y; Yu X; Gonzales F; Mangelsdorf DJ; Wang MY; Richardson C; Witters LA; Unger RH. 2002. PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci U S A 99(18):11848-53. [PubMed: 12195019]  [MGI Ref ID J:78908]

Leone TC; Weinheimer CJ; Kelly DP. 1999. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A 96(13):7473-8. [PubMed: 10377439]  [MGI Ref ID J:56056]

Lewitt MS; Brismar K. 2002. Gender difference in the leptin response to feeding in peroxisome-proliferator-activated receptor-alpha knockout mice. Int J Obes Relat Metab Disord 26(10):1296-300. [PubMed: 12355324]  [MGI Ref ID J:102646]

Li D; Zhang Y; Xu L; Zhou L; Wang Y; Xue B; Wen Z; Li P; Sang J. 2010. Regulation of gene expression by FSP27 in white and brown adipose tissue. BMC Genomics 11:446. [PubMed: 20649970]  [MGI Ref ID J:162769]

Li F; Patterson AD; Krausz KW; Tanaka N; Gonzalez FJ. 2012. Metabolomics reveals an essential role for peroxisome proliferator-activated receptor alpha in bile acid homeostasis. J Lipid Res 53(8):1625-35. [PubMed: 22665165]  [MGI Ref ID J:186557]

Li Y; Nara TY; Nakamura MT. 2005. Peroxisome proliferator-activated receptor alpha is required for feedback regulation of highly unsaturated fatty acid synthesis. J Lipid Res 46(11):2432-40. [PubMed: 16106047]  [MGI Ref ID J:104774]

Li Y; Yin R; Liu J; Wang P; Wu S; Luo J; Zhelyabovska O; Yang Q. 2009. Peroxisome proliferator-activated receptor delta regulates mitofusin 2 expression in the heart. J Mol Cell Cardiol 46(6):876-82. [PubMed: 19265701]  [MGI Ref ID J:157147]

Linden D; Alsterholm M; Wennbo H; Oscarsson J. 2001. PPARalpha deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins. J Lipid Res 42(11):1831-40. [PubMed: 11714852]  [MGI Ref ID J:123426]

Ljungberg A; Linden D; Ameen C; Bergstrom G; Oscarsson J. 2007. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism. Growth Horm IGF Res 17(2):154-64. [PubMed: 17307376]  [MGI Ref ID J:124483]

Loichot C; Jesel L; Tesse A; Tabernero A; Schoonjans K; Roul G; Carpusca I; Auwerx J; Andriantsitohaina R. 2006. Deletion of peroxisome proliferator-activated receptor-alpha induces an alteration of cardiac functions. Am J Physiol Heart Circ Physiol 291(1):H161-6. [PubMed: 16461373]  [MGI Ref ID J:116298]

Longuet C; Sinclair EM; Maida A; Baggio LL; Maziarz M; Charron MJ; Drucker DJ. 2008. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab 8(5):359-71. [PubMed: 19046568]  [MGI Ref ID J:143752]

Lu B; Jiang YJ; Zhou Y; Xu FY; Hatch GM; Choy PC. 2005. Cloning and characterization of murine 1-acyl-sn-glycerol 3-phosphate acyltransferases and their regulation by PPARalpha in murine heart. Biochem J 385(Pt 2):469-77. [PubMed: 15367102]  [MGI Ref ID J:104512]

Lu Y; Liu X; Jiao Y; Xiong X; Wang E; Wang X; Zhang Z; Zhang H; Pan L; Guan Y; Cai D; Ning G; Li X. 2014. Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARalpha. J Clin Invest 124(8):3501-13. [PubMed: 25003192]  [MGI Ref ID J:213849]

Luptak I; Balschi JA; Xing Y; Leone TC; Kelly DP; Tian R. 2005. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 112(15):2339-46. [PubMed: 16203912]  [MGI Ref ID J:116856]

Maida A; Lamont BJ; Cao X; Drucker DJ. 2011. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia 54(2):339-49. [PubMed: 20972533]  [MGI Ref ID J:169580]

Makowski L; Noland RC; Koves TR; Xing W; Ilkayeva OR; Muehlbauer MJ; Stevens RD; Muoio DM. 2009. Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation. FASEB J 23(2):586-604. [PubMed: 18945875]  [MGI Ref ID J:146023]

Marionneau C; Aimond F; Brunet S; Niwa N; Finck B; Kelly DP; Nerbonne JM. 2008. PPARalpha-mediated remodeling of repolarizing voltage-gated K+ (Kv) channels in a mouse model of metabolic cardiomyopathy. J Mol Cell Cardiol 44(6):1002-15. [PubMed: 18482733]  [MGI Ref ID J:137542]

Martens K; Ver Loren van Themaat E; van Batenburg MF; Heinaniemi M; Huyghe S; Van Hummelen P; Carlberg C; Van Veldhoven PP; Van Kampen A; Baes M. 2008. Coordinate induction of PPARalpha and SREBP2 in multifunctional protein 2 deficient mice. Biochim Biophys Acta 1781(11-12):694-702. [PubMed: 18773970]  [MGI Ref ID J:142427]

Martin LJ; Tremblay JJ. 2010. Nuclear receptors in leydig cell gene expression and function. Biol Reprod 83(1):3-14. [PubMed: 20375256]  [MGI Ref ID J:161974]

Martinez-Jimenez CP; Kyrmizi I; Cardot P; Gonzalez FJ; Talianidis I. 2010. Hepatocyte nuclear factor 4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism. Mol Cell Biol 30(3):565-77. [PubMed: 19933841]  [MGI Ref ID J:156389]

Mazzon E; Crisafulli C; Galuppo M; Cuzzocrea S. 2009. Role of peroxisome proliferator-activated receptor-alpha in ileum tight junction alteration in mouse model of restraint stress. Am J Physiol Gastrointest Liver Physiol 297(3):G488-505. [PubMed: 19556362]  [MGI Ref ID J:152101]

Mazzucotelli A; Viguerie N; Tiraby C; Annicotte JS; Mairal A; Klimcakova E; Lepin E; Delmar P; Dejean S; Tavernier G; Lefort C; Hidalgo J; Pineau T; Fajas L; Clement K; Langin D. 2007. The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes independently of PPAR gamma activation in human white adipocytes. Diabetes 56(10):2467-75. [PubMed: 17646210]  [MGI Ref ID J:126548]

Michalik L; Desvergne B; Tan NS; Basu-Modak S; Escher P; Rieusset J; Peters JM; Kaya G; Gonzalez FJ; Zakany J; Metzger D; Chambon P; Duboule D; Wahli W. 2001. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 154(4):799-814. [PubMed: 11514592]  [MGI Ref ID J:71272]

Miyazaki M; Dobrzyn A; Sampath H; Lee SH; Man WC; Chu K; Peters JM; Gonzalez FJ; Ntambi JM. 2004. Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome proliferator-activated receptor-alpha. J Biol Chem 279(33):35017-24. [PubMed: 15180999]  [MGI Ref ID J:92232]

Moffit JS; Koza-Taylor PH; Holland RD; Thibodeau MS; Beger RD; Lawton MP; Manautou JE. 2007. Differential gene expression in mouse liver associated with the hepatoprotective effect of clofibrate. Toxicol Appl Pharmacol 222(2):169-79. [PubMed: 17585979]  [MGI Ref ID J:122987]

Motojima K. 2004. 17beta-hydroxysteroid dehydrogenase type 11 is a major peroxisome proliferator-activated receptor alpha-regulated gene in mouse intestine. Eur J Biochem 271(20):4141-6. [PubMed: 15479243]  [MGI Ref ID J:115498]

Motojima K; Peters JM; Gonzalez FJ. 1997. PPAR alpha mediates peroxisome proliferator-induced transcriptional repression of nonperoxisomal gene expression in mouse. Biochem Biophys Res Commun 230(1):155-8. [PubMed: 9020034]  [MGI Ref ID J:37564]

Muoio DM; MacLean PS; Lang DB; Li S; Houmard JA; Way JM; Winegar DA; Corton JC; Dohm GL; Kraus WE. 2002. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J Biol Chem 277(29):26089-97. [PubMed: 12118038]  [MGI Ref ID J:77924]

Nakajima T; Kamijo Y; Tanaka N; Sugiyama E; Tanaka E; Kiyosawa K; Fukushima Y; Peters JM; Gonzalez FJ; Aoyama T. 2004. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology 40(4):972-80. [PubMed: 15382117]  [MGI Ref ID J:105578]

Nakajima T; Kamijo Y; Usuda N; Liang Y; Fukushima Y; Kametani K; Gonzalez FJ; Aoyama T. 2000. Sex-dependent regulation of hepatic peroxisome proliferation in mice by trichloroethylene via peroxisome proliferator-activated receptor alpha (PPARalpha). Carcinogenesis 21(4):677-82. [PubMed: 10753203]  [MGI Ref ID J:61785]

Nakajima T; Tanaka N; Sugiyama E; Kamijo Y; Hara A; Hu R; Li G; Li Y; Nakamura K; Gonzalez FJ; Aoyama T. 2008. Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice. Biochem Pharmacol 76(1):108-19. [PubMed: 18486101]  [MGI Ref ID J:137917]

Neschen S; Morino K; Dong J; Wang-Fischer Y; Cline GW; Romanelli AJ; Rossbacher JC; Moore IK; Regittnig W; Munoz DS; Kim JH; Shulman GI. 2007. n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes 56(4):1034-41. [PubMed: 17251275]  [MGI Ref ID J:122120]

Newaz M; Blanton A; Fidelis P; Oyekan A. 2005. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects. Mutat Res 579(1-2):163-71. [PubMed: 16054168]  [MGI Ref ID J:102276]

Nohammer C; Brunner F; Wolkart G; Staber PB; Steyrer E; Gonzalez FJ; Zechner R; Hoefler G. 2003. Myocardial dysfunction and male mortality in peroxisome proliferator-activated receptor alpha knockout mice overexpressing lipoprotein lipase in muscle. Lab Invest 83(2):259-69. [PubMed: 12594240]  [MGI Ref ID J:82220]

Oishi K; Uchida D; Ishida N. 2008. Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver. FEBS Lett 582(25-26):3639-42. [PubMed: 18840432]  [MGI Ref ID J:143421]

Oka S; Alcendor R; Zhai P; Park JY; Shao D; Cho J; Yamamoto T; Tian B; Sadoshima J. 2011. PPARalpha-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab 14(5):598-611. [PubMed: 22055503]  [MGI Ref ID J:179686]

Panagia M; Gibbons GF; Radda GK; Clarke K. 2005. PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol Heart Circ Physiol 288(6):H2677-83. [PubMed: 15665064]  [MGI Ref ID J:99885]

Panigrahy D; Kaipainen A; Huang S; Butterfield CE; Barnes CM; Fannon M; Laforme AM; Chaponis DM; Folkman J; Kieran MW. 2008. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A 105(3):985-90. [PubMed: 18199835]  [MGI Ref ID J:131414]

Park CW; Kim HW; Ko SH; Chung HW; Lim SW; Yang CW; Chang YS; Sugawara A; Guan Y; Breyer MD. 2006. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. Diabetes 55(4):885-93. [PubMed: 16567507]  [MGI Ref ID J:108598]

Patel DD; Knight BL; Wiggins D; Humphreys SM; Gibbons GF. 2001. Disturbances in the normal regulation of SREBP-sensitive genes in PPAR alpha-deficient mice. J Lipid Res 42(3):328-37. [PubMed: 11254743]  [MGI Ref ID J:68345]

Patsouris D; Mandard S; Voshol PJ; Escher P; Tan NS; Havekes LM; Koenig W; Marz W; Tafuri S; Wahli W; Muller M; Kersten S. 2004. PPARalpha governs glycerol metabolism. J Clin Invest 114(1):94-103. [PubMed: 15232616]  [MGI Ref ID J:91368]

Paumelle R; Blanquart C; Briand O; Barbier O; Duhem C; Woerly G; Percevault F; Fruchart JC; Dombrowicz D; Glineur C; Staels B. 2006. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 98(3):361-9. [PubMed: 16397146]  [MGI Ref ID J:118877]

Pedraza N; Rosell M; Villarroya J; Iglesias R; Gonzalez FJ; Solanes G; Villarroya F. 2006. Developmental and tissue-specific involvement of peroxisome proliferator-activated receptor-alpha in the control of mouse uncoupling protein-3 gene expression. Endocrinology 147(10):4695-704. [PubMed: 16857752]  [MGI Ref ID J:129546]

Peters JM; Park Y; Gonzalez FJ; Pariza MW. 2001. Influence of conjugated linoleic acid on body composition and target gene expression in peroxisome proliferator-activated receptor alpha-null mice. Biochim Biophys Acta 1533(3):233-42. [PubMed: 11731333]  [MGI Ref ID J:72806]

Petrescu AD; Huang H; Martin GG; McIntosh AL; Storey SM; Landrock D; Kier AB; Schroeder F. 2013. Impact of L-FABP and glucose on polyunsaturated fatty acid induction of PPARalpha-regulated beta-oxidative enzymes. Am J Physiol Gastrointest Liver Physiol 304(3):G241-56. [PubMed: 23238934]  [MGI Ref ID J:194850]

Petrescu AD; McIntosh AL; Storey SM; Huang H; Martin GG; Landrock D; Kier AB; Schroeder F. 2013. High glucose potentiates L-FABP mediated fibrate induction of PPARalpha in mouse hepatocytes. Biochim Biophys Acta 1831(8):1412-25. [PubMed: 23747828]  [MGI Ref ID J:202533]

Planavila A; Iglesias R; Giralt M; Villarroya F. 2011. Sirt1 acts in association with PPARalpha to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res 90(2):276-84. [PubMed: 21115502]  [MGI Ref ID J:186032]

Poynter ME; Daynes RA. 1998. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273(49):32833-41. [PubMed: 9830030]  [MGI Ref ID J:51328]

Pozzi A; Popescu V; Yang S; Mei S; Shi M; Puolitaival SM; Caprioli RM; Capdevila JH. 2010. The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. J Biol Chem 285(17):12840-50. [PubMed: 20178979]  [MGI Ref ID J:207597]

Pruimboom-Brees I; Haghpassand M; Royer L; Brees D; Aldinger C; Reagan W; Singh J; Kerlin R; Kane C; Bagley S; Hayward C; Loy J; O'Brien P; Francone OL. 2006. A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis. Am J Pathol 169(3):750-60. [PubMed: 16936252]  [MGI Ref ID J:112362]

Qiao L; Lee B; Kinney B; Yoo HS; Shao J. 2011. Energy intake and adiponectin gene expression. Am J Physiol Endocrinol Metab 300(5):E809-16. [PubMed: 21325106]  [MGI Ref ID J:172309]

Ringseis R; Keller J; Lukas I; Spielmann J; Most E; Couturier A; Konig B; Hirche F; Stangl GI; Wen G; Eder K. 2013. Treatment with pharmacological PPARalpha agonists stimulates the ubiquitin proteasome pathway and myofibrillar protein breakdown in skeletal muscle of rodents. Biochim Biophys Acta 1830(1):2105-17. [PubMed: 23041501]  [MGI Ref ID J:192038]

Roberts LD; Bostrom P; O'Sullivan JF; Schinzel RT; Lewis GD; Dejam A; Lee YK; Palma MJ; Calhoun S; Georgiadi A; Chen MH; Ramachandran VS; Larson MG; Bouchard C; Rankinen T; Souza AL; Clish CB; Wang TJ; Estall JL; Soukas AA; Cowan CA; Spiegelman BM; Gerszten RE. 2014. beta-Aminoisobutyric acid induces browning of white fat and hepatic beta-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab 19(1):96-108. [PubMed: 24411942]  [MGI Ref ID J:210544]

Rommelaere S; Millet V; Gensollen T; Bourges C; Eeckhoute J; Hennuyer N; Bauge E; Chasson L; Cacciatore I; Staels B; Pitari G; Galland F; Naquet P. 2013. PPARalpha regulates the production of serum Vanin-1 by liver. FEBS Lett 587(22):3742-8. [PubMed: 24140347]  [MGI Ref ID J:205603]

Rosell M; Hondares E; Iwamoto S; Gonzalez FJ; Wabitsch M; Staels B; Olmos Y; Monsalve M; Giralt M; Iglesias R; Villarroya F. 2012. Peroxisome proliferator-activated receptors-alpha and -gamma, and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue. Endocrinology 153(3):1162-73. [PubMed: 22253419]  [MGI Ref ID J:182546]

Rost TH; Haugan Moi LL; Berge K; Staels B; Mellgren G; Berge RK. 2009. A pan-PPAR ligand induces hepatic fatty acid oxidation in PPARalpha-/- mice possibly through PGC-1 mediated PPARdelta coactivation. Biochim Biophys Acta 1791(11):1076-83. [PubMed: 19577662]  [MGI Ref ID J:164857]

Roy A; Jana M; Corbett GT; Ramaswamy S; Kordower JH; Gonzalez FJ; Pahan K. 2013. Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor alpha. Cell Rep 4(4):724-37. [PubMed: 23972989]  [MGI Ref ID J:202856]

Saez E; Olson P; Evans RM. 2003. Genetic deficiency in Pparg does not alter development of experimental prostate cancer. Nat Med 9(10):1265-1266. [PubMed: 12960963]  [MGI Ref ID J:86096]

Saito H; Terada T; Shimakura J; Katsura T; Inui K. 2008. Regulatory mechanism governing the diurnal rhythm of intestinal H+/peptide cotransporter 1 (PEPT1). Am J Physiol Gastrointest Liver Physiol 295(2):G395-402. [PubMed: 18583459]  [MGI Ref ID J:138615]

Sambandam N; Morabito D; Wagg C; Finck BN; Kelly DP; Lopaschuk GD. 2006. Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 290(1):H87-95. [PubMed: 16155108]  [MGI Ref ID J:104776]

Sanderson LM; Degenhardt T; Koppen A; Kalkhoven E; Desvergne B; Muller M; Kersten S. 2009. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) but not PPARalpha serves as a plasma free fatty acid sensor in liver. Mol Cell Biol 29(23):6257-67. [PubMed: 19805517]  [MGI Ref ID J:154988]

Savas U; Machemer DE; Hsu MH; Gaynor P; Lasker JM; Tukey RH; Johnson EF. 2009. Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. J Biol Chem 284(24):16541-52. [PubMed: 19366684]  [MGI Ref ID J:151352]

Schmuth M; Haqq CM; Cairns WJ; Holder JC; Dorsam S; Chang S; Lau P; Fowler AJ; Chuang G; Moser AH; Brown BE; Mao-Qiang M; Uchida Y; Schoonjans K; Auwerx J; Chambon P; Willson TM; Elias PM; Feingold KR. 2004. Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 122(4):971-83. [PubMed: 15102088]  [MGI Ref ID J:89329]

Schmuth M; Schoonjans K; Yu QC; Fluhr JW; Crumrine D; Hachem JP; Lau P; Auwerx J; Elias PM; Feingold KR. 2002. Role of Peroxisome Proliferator-Activated Receptor alpha in Epidermal Development in Utero. J Invest Dermatol 119(6):1298-303. [PubMed: 12485431]  [MGI Ref ID J:81021]

Sehic A; Khuu C; Risnes S; Osmundsen H. 2009. Differential gene expression profiling of the molar tooth germ in peroxisome proliferator-activated receptor-alpha (PPAR-alpha) knockout mouse and in wild-type mouse: molar tooth phenotype of PPAR-alpha knockout mouse. Eur J Oral Sci 117(2):93-104. [PubMed: 19320717]  [MGI Ref ID J:147982]

Shah YM; Morimura K; Yang Q; Tanabe T; Takagi M; Gonzalez FJ. 2007. Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol 27(12):4238-47. [PubMed: 17438130]  [MGI Ref ID J:122358]

Shibata N; Jishage K; Arita M; Watanabe M; Kawase Y; Nishikawa K; Natori Y; Inoue H; Shimano H; Yamada N; Tsujimoto M; Arai H. 2006. Regulation of hepatic cholesterol synthesis by a novel protein (SPF) that accelerates cholesterol biosynthesis. FASEB J 20(14):2642-4. [PubMed: 17077281]  [MGI Ref ID J:129749]

Silvennoinen R; Escola-Gil JC; Julve J; Rotllan N; Llaverias G; Metso J; Valledor AF; He J; Yu L; Jauhiainen M; Blanco-Vaca F; Kovanen PT; Lee-Rueckert M. 2012. Acute psychological stress accelerates reverse cholesterol transport via corticosterone-dependent inhibition of intestinal cholesterol absorption. Circ Res 111(11):1459-69. [PubMed: 22931956]  [MGI Ref ID J:212624]

Smeets PJ; Teunissen BE; Willemsen PH; van Nieuwenhoven FA; Brouns AE; Janssen BJ; Cleutjens JP; Staels B; van der Vusse GJ; van Bilsen M. 2008. Cardiac hypertrophy is enhanced in PPAR alpha-/- mice in response to chronic pressure overload. Cardiovasc Res 78(1):79-89. [PubMed: 18187461]  [MGI Ref ID J:161909]

Smeets PJ; de Vogel-van den Bosch HM; Willemsen PH; Stassen AP; Ayoubi T; van der Vusse GJ; van Bilsen M. 2008. Transcriptomic analysis of PPARalpha-dependent alterations during cardiac hypertrophy. Physiol Genomics 36(1):15-23. [PubMed: 18812456]  [MGI Ref ID J:145452]

Solorzano C; Zhu C; Battista N; Astarita G; Lodola A; Rivara S; Mor M; Russo R; Maccarrone M; Antonietti F; Duranti A; Tontini A; Cuzzocrea S; Tarzia G; Piomelli D. 2009. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A 106(49):20966-71. [PubMed: 19926854]  [MGI Ref ID J:155551]

Son NH; Ananthakrishnan R; Yu S; Khan RS; Jiang H; Ji R; Akashi H; Li Q; O'Shea K; Homma S; Goldberg IJ; Ramasamy R. 2012. Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia. PLoS One 7(9):e46549. [PubMed: 23029549]  [MGI Ref ID J:191958]

Son NH; Yu S; Tuinei J; Arai K; Hamai H; Homma S; Shulman GI; Abel ED; Goldberg IJ. 2010. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Invest 120(10):3443-54. [PubMed: 20852389]  [MGI Ref ID J:165259]

Stienstra R; Mandard S; Patsouris D; Maass C; Kersten S; Muller M. 2007. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology 148(6):2753-63. [PubMed: 17347305]  [MGI Ref ID J:129622]

Su Q; Baker C; Christian P; Naples M; Tong X; Zhang K; Santha M; Adeli K. 2014. Hepatic mitochondrial and ER stress induced by defective PPARalpha signaling in the pathogenesis of hepatic steatosis. Am J Physiol Endocrinol Metab 306(11):E1264-73. [PubMed: 24735884]  [MGI Ref ID J:213608]

Sugden MC; Bulmer K; Gibbons GF; Holness MJ. 2001. Role of Peroxisome Proliferator-Activated Receptor-alpha in the Mechanism Underlying Changes in Renal Pyruvate Dehydrogenase Kinase Isoform 4 Protein Expression in Starvation and after Refeeding. Arch Biochem Biophys 395(2):246-52. [PubMed: 11697863]  [MGI Ref ID J:72837]

Sugden MC; Bulmer K; Gibbons GF; Knight BL; Holness MJ. 2002. Peroxisome-proliferator-activated receptor-alpha (PPARalpha) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin. Biochem J 364(Pt 2):361-8. [PubMed: 12023878]  [MGI Ref ID J:113527]

Sugiyama E; Tanaka N; Nakajima T; Kamijo Y; Yokoyama S; Li Y; Gonzalez FJ; Aoyama T. 2006. Haploinsufficiency in the PPARalpha and LDL receptor genes leads to gender- and age-specific obesity and hyperinsulinemia. Biochem Biophys Res Commun 350(2):370-6. [PubMed: 17011521]  [MGI Ref ID J:116049]

Sun L; Xie H; Mori MA; Alexander R; Yuan B; Hattangadi SM; Liu Q; Kahn CR; Lodish HF. 2011. Mir193b-365 is essential for brown fat differentiation. Nat Cell Biol 13(8):958-65. [PubMed: 21743466]  [MGI Ref ID J:174421]

Sunny NE; Satapati S; Fu X; He T; Mehdibeigi R; Spring-Robinson C; Duarte J; Potthoff MJ; Browning JD; Burgess SC. 2010. Progressive adaptation of hepatic ketogenesis in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 298(6):E1226-35. [PubMed: 20233938]  [MGI Ref ID J:162879]

Takashima K; Ito Y; Gonzalez FJ; Nakajima T. 2008. Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Ppar alpha-null mice. J Occup Health 50(2):169-80. [PubMed: 18403868]  [MGI Ref ID J:138511]

Tanaka N; Moriya K; Kiyosawa K; Koike K; Gonzalez FJ; Aoyama T. 2008. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 118(2):683-94. [PubMed: 18188449]  [MGI Ref ID J:131298]

Tong Y; Hara A; Komatsu M; Tanaka N; Kamijo Y; Gonzalez FJ; Aoyama T. 2005. Suppression of expression of muscle-associated proteins by PPARalpha in brown adipose tissue. Biochem Biophys Res Commun 336(1):76-83. [PubMed: 16125138]  [MGI Ref ID J:100946]

Tordjman K; Bernal-Mizrachi C; Zemany L; Weng S; Feng C; Zhang F; Leone TC; Coleman T; Kelly DP; Semenkovich CF. 2001. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 107(8):1025-34. [PubMed: 11306606]  [MGI Ref ID J:68880]

Trent CM; Yu S; Hu Y; Skoller N; Huggins LA; Homma S; Goldberg IJ. 2014. Lipoprotein lipase activity is required for cardiac lipid droplet production. J Lipid Res 55(4):645-58. [PubMed: 24493834]  [MGI Ref ID J:208767]

Upham J; Acott PD; O'regan P; Sinal CJ; Crocker JF; Geldenhuys L; Murphy MG. 2007. The pesticide adjuvant, Toximul, alters hepatic metabolism through effects on downstream targets of PPARalpha. Biochim Biophys Acta 1772(9):1057-64. [PubMed: 17643967]  [MGI Ref ID J:127050]

Valasek MA; Clarke SL; Repa JJ. 2007. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse. J Lipid Res 48(12):2725-35. [PubMed: 17726195]  [MGI Ref ID J:129975]

Vegiopoulos A; Muller-Decker K; Strzoda D; Schmitt I; Chichelnitskiy E; Ostertag A; Berriel Diaz M; Rozman J; Hrabe de Angelis M; Nusing RM; Meyer CW; Wahli W; Klingenspor M; Herzig S. 2010. Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. Science 328(5982):1158-61. [PubMed: 20448152]  [MGI Ref ID J:160553]

Villard PH; Caverni S; Baanannou A; Khalil A; Martin PG; Penel C; Pineau T; Seree E; Barra Y. 2007. PPARalpha transcriptionally induces AhR expression in Caco-2, but represses AhR pro-inflammatory effects. Biochem Biophys Res Commun 364(4):896-901. [PubMed: 17963696]  [MGI Ref ID J:128444]

Viswakarma N; Jia Y; Bai L; Gao Q; Lin B; Zhang X; Misra P; Rana A; Jain S; Gonzalez FJ; Zhu YJ; Thimmapaya B; Reddy JK. 2013. The Med1 subunit of the mediator complex induces liver cell proliferation and is phosphorylated by AMP kinase. J Biol Chem 288(39):27898-911. [PubMed: 23943624]  [MGI Ref ID J:203962]

Walden TB; Petrovic N; Nedergaard J. 2010. PPARalpha does not suppress muscle-associated gene expression in brown adipocytes but does influence expression of factors that fingerprint the brown adipocyte. Biochem Biophys Res Commun 397(2):146-51. [PubMed: 20471959]  [MGI Ref ID J:162429]

Walker CG; Holness MJ; Gibbons GF; Sugden MC. 2007. Fasting-induced increases in aquaporin 7 and adipose triglyceride lipase mRNA expression in adipose tissue are attenuated by peroxisome proliferator-activated receptor alpha deficiency. Int J Obes (Lond) 31(7):1165-71. [PubMed: 17245390]  [MGI Ref ID J:151294]

Walker CG; Sugden MC; Gibbons GF; Holness MJ. 2007. Peroxisome proliferator-activated receptor {alpha} deficiency modifies glucose handling by isolated mouse adipocytes. J Endocrinol 193(1):39-43. [PubMed: 17400801]  [MGI Ref ID J:120367]

Wang T; Shah YM; Matsubara T; Zhen Y; Tanabe T; Nagano T; Fotso S; Krausz KW; Zabriskie TM; Idle JR; Gonzalez FJ. 2010. Control of steroid 21-oic acid synthesis by peroxisome proliferator-activated receptor alpha and role of the hypothalamic-pituitary-adrenal axis. J Biol Chem 285(10):7670-85. [PubMed: 20032461]  [MGI Ref ID J:160724]

Watanabe K; Fujii H; Takahashi T; Kodama M; Aizawa Y; Ohta Y; Ono T; Hasegawa G; Naito M; Nakajima T; Kamijo Y; Gonzalez FJ; Aoyama T. 2000. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 275(29):22293-9. [PubMed: 10801788]  [MGI Ref ID J:63801]

Wejksza K; Lee-Chang C; Bodogai M; Bonzo J; Gonzalez FJ; Lehrmann E; Becker K; Biragyn A. 2013. Cancer-Produced Metabolites of 5-Lipoxygenase Induce Tumor-Evoked Regulatory B Cells via Peroxisome Proliferator-Activated Receptor alpha. J Immunol 190(6):2575-84. [PubMed: 23408836]  [MGI Ref ID J:193679]

Westin MA; Alexson SE; Hunt MC. 2004. Molecular cloning and characterization of two mouse peroxisome proliferator-activated receptor alpha (PPARalpha)-regulated peroxisomal acyl-CoA thioesterases. J Biol Chem 279(21):21841-8. [PubMed: 15007068]  [MGI Ref ID J:90430]

Whittle AJ; Carobbio S; Martins L; Slawik M; Hondares E; Vazquez MJ; Morgan D; Csikasz RI; Gallego R; Rodriguez-Cuenca S; Dale M; Virtue S; Villarroya F; Cannon B; Rahmouni K; Lopez M; Vidal-Puig A. 2012. BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell 149(4):871-85. [PubMed: 22579288]  [MGI Ref ID J:186179]

Wieneke N; Hirsch-Ernst KI; Kuna M; Kersten S; Puschel GP. 2007. PPARalpha-dependent induction of the energy homeostasis-regulating nuclear receptor NR1i3 (CAR) in rat hepatocytes: Potential role in starvation adaptation. FEBS Lett 581(29):5617-26. [PubMed: 18023279]  [MGI Ref ID J:127733]

Woerly G; Honda K; Loyens M; Papin JP; Auwerx J; Staels B; Capron M; Dombrowicz D. 2003. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med 198(3):411-21. [PubMed: 12900517]  [MGI Ref ID J:84840]

Wolins NE; Quaynor BK; Skinner JR; Tzekov A; Croce MA; Gropler MC; Varma V; Yao-Borengasser A; Rasouli N; Kern PA; Finck BN; Bickel PE. 2006. OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization. Diabetes 55(12):3418-28. [PubMed: 17130488]  [MGI Ref ID J:121011]

Wu P; Peters JM; Harris RA. 2001. Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun 287(2):391-6. [PubMed: 11554740]  [MGI Ref ID J:71824]

Wu X; Peters JM; Gonzalez FJ; Prasad HS; Rohrer MD; Gimble JM. 2000. Frequency of stromal lineage colony forming units in bone marrow of peroxisome proliferator-activated receptor-alpha-null mice. Bone 26(1):21-6. [PubMed: 10617153]  [MGI Ref ID J:60084]

Xu J; Chang V; Joseph SB; Trujillo C; Bassilian S; Saad MF; Lee WN; Kurland IJ. 2004. Peroxisomal proliferator-activated receptor alpha deficiency diminishes insulin-responsiveness of gluconeogenic/glycolytic/pentose gene expression and substrate cycle flux. Endocrinology 145(3):1087-95. [PubMed: 14670991]  [MGI Ref ID J:105595]

Xu J; Xiao G; Trujillo C; Chang V; Blanco L; Joseph SB; Bassilian S; Saad MF; Tontonoz P; Lee WN; Kurland IJ. 2002. Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production. J Biol Chem 277(52):50237-44. [PubMed: 12176975]  [MGI Ref ID J:81032]

Xu S; Zhu BT; Turan V; Rusyn I; Thurman R; Peters JM; Gonzalez FJ; Conney AH. 2001. PPARalpha-dependent induction of liver microsomal esterification of estradiol and testosterone by a prototypical peroxisome proliferator. Endocrinology 142(8):3554-7. [PubMed: 11459802]  [MGI Ref ID J:115613]

Yang CS; Yuk JM; Kim JJ; Hwang JH; Lee CH; Kim JM; Oh GT; Choi HS; Jo EK. 2013. Small heterodimer partner-targeting therapy inhibits systemic inflammatory responses through mitochondrial uncoupling protein 2. PLoS One 8(5):e63435. [PubMed: 23704907]  [MGI Ref ID J:200840]

Yang Q; Nagano T; Shah Y; Cheung C; Ito S; Gonzalez FJ. 2008. The PPAR{alpha}-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPAR{alpha}. Toxicol Sci 101(1):132-9. [PubMed: 17690133]  [MGI Ref ID J:129053]

Yang Q; Xie Y; Alexson SE; Nelson BD; DePierre JW. 2002. Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. Biochem Pharmacol 63(10):1893-900. [PubMed: 12034374]  [MGI Ref ID J:77391]

Yessoufou A; Hichami A; Besnard P; Moutairou K; Khan NA. 2006. Peroxisome proliferator-activated receptor alpha deficiency increases the risk of maternal abortion and neonatal mortality in murine pregnancy with or without diabetes mellitus: Modulation of T cell differentiation. Endocrinology 147(9):4410-8. [PubMed: 16763063]  [MGI Ref ID J:129524]

Yoo SH; Abdelmegeed MA; Song BJ. 2013. Activation of PPARalpha by Wy-14643 ameliorates systemic lipopolysaccharide-induced acute lung injury. Biochem Biophys Res Commun 436(3):366-71. [PubMed: 23727576]  [MGI Ref ID J:204426]

Young ME; Patil S; Ying J; Depre C; Ahuja HS; Shipley GL; Stepkowski SM; Davies PJ; Taegtmeyer H. 2001. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. FASEB J 15(3):833-45. [PubMed: 11259402]  [MGI Ref ID J:67943]

Yubero P; Hondares E; Carmona MC; Rossell M; Gonzalez FJ; Iglesias R; Giralt M; Villarroya F. 2004. The developmental regulation of peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression in the liver is partially dissociated from the control of gluconeogenesis and lipid catabolism. Endocrinology 145(9):4268-77. [PubMed: 15178647]  [MGI Ref ID J:91859]

Zandbergen F; Mandard S; Escher P; Tan NS; Patsouris D; Jatkoe T; Rojas-Caro S; Madore S; Wahli W; Tafuri S; Muller M; Kersten S. 2005. The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem J 392(Pt 2):313-24. [PubMed: 16086669]  [MGI Ref ID J:117571]

Zhang H; Shen WJ; Cortez Y; Kraemer FB; Azhar S. 2013. Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARalpha-dependent and -independent pathways. Am J Physiol Gastrointest Liver Physiol 304(1):G72-86. [PubMed: 23104557]  [MGI Ref ID J:194703]

Zhang MA; Rego D; Moshkova M; Kebir H; Chruscinski A; Nguyen H; Akkermann R; Stanczyk FZ; Prat A; Steinman L; Dunn SE. 2012. Peroxisome proliferator-activated receptor (PPAR)alpha and -gamma regulate IFNgamma and IL-17A production by human T cells in a sex-specific way. Proc Natl Acad Sci U S A 109(24):9505-10. [PubMed: 22647601]  [MGI Ref ID J:185518]

Zhang X; Nakajima T; Kamijo Y; Li G; Hu R; Kannagi R; Kyogashima M; Aoyama T; Hara A. 2009. Acute kidney injury induced by protein-overload nephropathy down-regulates gene expression of hepatic cerebroside sulfotransferase in mice, resulting in reduction of liver and serum sulfatides. Biochem Biophys Res Commun 390(4):1382-8. [PubMed: 19895791]  [MGI Ref ID J:155597]

Zhang X; Tanaka N; Nakajima T; Kamijo Y; Gonzalez FJ; Aoyama T. 2006. Peroxisome proliferator-activated receptor alpha-independent peroxisome proliferation. Biochem Biophys Res Commun 346(4):1307-11. [PubMed: 16806075]  [MGI Ref ID J:110500]

Zhen Y; Krausz KW; Chen C; Idle JR; Gonzalez FJ. 2007. Metabolomic and Genetic Analysis of Biomarkers for Peroxisome Proliferator-Activated Receptor {alpha} Expression and Activation. Mol Endocrinol 21(9):2136-51. [PubMed: 17550978]  [MGI Ref ID J:124087]

Zhou Y; Kong X; Zhao P; Yang H; Chen L; Miao J; Zhang X; Yang J; Ding J; Guan Y. 2011. Peroxisome proliferator-activated receptor-alpha is renoprotective in doxorubicin-induced glomerular injury. Kidney Int 79(12):1302-11. [PubMed: 21368746]  [MGI Ref ID J:186870]

Ziouzenkova O; Perrey S; Asatryan L; Hwang J; MacNaul KL; Moller DE; Rader DJ; Sevanian A; Zechner R; Hoefler G; Plutzky J. 2003. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc Natl Acad Sci U S A 100(5):2730-5. [PubMed: 12606719]  [MGI Ref ID J:82391]

van Vlies N; Ferdinandusse S; Turkenburg M; Wanders RJ; Vaz FM. 2007. PPAR alpha-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation. Biochim Biophys Acta 1767(9):1134-42. [PubMed: 17692817]  [MGI Ref ID J:127048]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX10

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, these mice can be bred as homozygotes.
Mating SystemHomozygote x Homozygote         (Female x Male)   05-SEP-08
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $199.90Female or MaleHomozygous for Pparatm1Gonz  
Price per Pair (US dollars $)Pair Genotype
$399.80Homozygous for Pparatm1Gonz x Homozygous for Pparatm1Gonz  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $259.90Female or MaleHomozygous for Pparatm1Gonz  
Price per Pair (US dollars $)Pair Genotype
$519.80Homozygous for Pparatm1Gonz x Homozygous for Pparatm1Gonz  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

  Control
   000664 C57BL/6J (approximate)
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)